Substance / Medication

Methazolamide

Overview

Active Ingredient
methazolamide
RxNorm CUI
6826

Indications

Methazolamide Tablets, USP are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.

Labeler: Ajanta Pharma USA Inc.Updated: 2026-02-10T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Methazolamide therapy is contraindicated in situations in which sodium and/or potassium serum levels are depressed, in cases of marked kidney or liver disease or dysfunction, in adrenal gland failure, and in hyperchloremic acidosis. In patients with cirrhosis, use may precipitate the development of

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis.
Tangamornsuksan Wimonchat, Lohitnavy Manupat · Pharmacogenomics J · 2019
PMID: 30242287Meta-Analysis
Effects of the low Fowler's sleep position and methazolamide treatment on sleep bruxism: A randomized controlled trial.
Zhong Zhijun, Li Qi, Zou Xueliang et al. · J Sleep Res · 2025
PMID: 38803083RCT
Methazolamide Plus Aminophylline Abrogates Hypoxia-Mediated Endurance Exercise Impairment.
Scalzo Rebecca L, Binns Scott E, Klochak Anna L et al. · High Alt Med Biol · 2015
PMID: 26680684RCT
Efficacy and safety of oral methazolamide in patients with type 2 diabetes: a 24-week, placebo-controlled, double-blind study.
Simpson Richard W, Nicholson Geoffrey C, Proietto Joseph et al. · Diabetes Care · 2014
PMID: 25125506RCT
Influence of methazolamide on the human control of breathing: A comparison to acetazolamide.
Teppema Luc J, Boulet Lindsey M, Hackett Heather K et al. · Exp Physiol · 2020
PMID: 31595565Observational
Effect of acetazolamide and methazolamide on diaphragm and dorsiflexor fatigue: a randomized controlled trial.
Dominelli Paolo B, McNeil Chris J, Vermeulen Tyler D et al. · J Appl Physiol (1985) · 2018
PMID: 29792554Observational
A Randomized Pilot Study of Four Dosing Schemes of Sublingual Methazolamide in Glaucoma Patients.
Tan Nicholas E, Patnaik Jennifer L, McWilliams Sara et al. · Clin Ophthalmol · 2024
PMID: 39726639Case ReportFull text (PMC)
Association of HLA-C*01:02 with methazolamide-induced toxic epidermal necrolysis.
Qiumei Gu, Zhengju Chen, Xuefei He et al. · BMJ Case Rep · 2022
PMID: 36572447Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Methazolamide (substance)
SNOMED CT
53052005
UMLS CUI
C0025631
RxNorm CUI
6826
Labeler
Ajanta Pharma USA Inc.

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.